Immunotherapy plus chemo before bladder surgery for advanced cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies giving toripalimab (an immunotherapy) together with gemcitabine and cisplatin before bladder surgery. It aims to shrink locally advanced bladder cancer and make surgery more effective by using the immune system and chemotherapy together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75 when you sign consent
- You have locally advanced urothelial bladder cancer (no spread to distant organs, and not too many lymph nodes)
- You have not had any anti-cancer treatment systemically yet (no prior anti–PD-1/PD-L1/CTLA-4 antibodies or chemo; bladder-infusion chemo is allowed)
- A scan shows at least one measurable tumor spot (CT lesion at least 10 mm)
- Your health is strong enough for treatment: you must have good blood counts and key lab values, and you need kidney function that meets the study limits
- You must be able to plan for radical cystectomy (bladder removal) and follow study visits, including providing tumor tissue samples
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of immunotherapy (tislelizumab) plus chemotherapy (cisplatin and gemcitabine) with or without an extra drug (trilaciclib) for people with advanced bladder cancer that hasn't been treated yet. The goal is to see if this combination is safe and helps shrink tumors.
This trial tests a new combination of two drugs—9MW2821 (an antibody-drug conjugate) and Toripalimab (an immunotherapy)—given before and after surgery for muscle-invasive or high-risk urothelial cancer that has not spread. The goal is to see if this combined treatment can improve outcomes.
This trial tests two drugs (RC48 and toripalimab) given before bladder cancer surgery for patients who cannot take the standard chemotherapy due to kidney problems or other reasons. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of two drugs (Tislelizumab and Palbociclib) given before bladder removal surgery. It is for people with bladder cancer that has a specific genetic change and who cannot take the standard chemotherapy cisplatin.
This trial tests adding a blood pressure medication (propranolol) to a combination of immunotherapy (tislelizumab) and chemotherapy before surgery for bladder cancer that has spread to lymph nodes. It aims to see if this can help shrink the tumor before it is removed.
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
Hear when a new Urinary Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.